Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL-1 Positive”

191 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 191 results

Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07134556
What this trial is testing

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast CancerPDL-1 Positive
MedSIR 25
Testing effectiveness (Phase 2)Study completedNCT04665843
What this trial is testing

Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Hoffmann-La Roche 123
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)Study completedNCT02628132
What this trial is testing

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 22
Not applicableUnknownNCT05110950
What this trial is testing

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Who this might be right for
Mediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more
Università Politecnica delle Marche 306
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Not applicableLooking for participantsNCT07038928
What this trial is testing

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Who this might be right for
Bladder Cancer
AstraZeneca 600
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)UnknownNCT05004974
What this trial is testing

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07459738
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Shanghai Henlius Biotech 60
Testing effectiveness (Phase 2)WithdrawnNCT04470674
What this trial is testing

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Who this might be right for
Lung CancerNon-small Cell Lung CancerPD-L1 Gene Mutation+1 more
Shirish M Gadgeel
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 25
Large-scale testing (Phase 3)Study completedNCT05064059
What this trial is testing

Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 441
Early research (Phase 1)WithdrawnNCT01452334
What this trial is testing

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Who this might be right for
Non-Hodgkin's LymphomaHodgkin LymphomaMultiple Myeloma+1 more
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Looking for participantsNCT06070012
What this trial is testing

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Who this might be right for
Uveal Melanoma
Diwakar Davar 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05879822
What this trial is testing

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Who this might be right for
Advanced Solid Tumor
Incyte Corporation 73
Testing effectiveness (Phase 2)WithdrawnNCT05879484
What this trial is testing

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Who this might be right for
Sinonasal CancerSquamous Non-small Cell Lung CancerLung Cancer+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT05859477
What this trial is testing

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerPD-L1 Gene AmplificationFGFR2 Amplification
Kidney Cancer Research Bureau 23
Early research (Phase 1)Looking for participantsNCT06084286
What this trial is testing

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan University 29
Load More Results